Status:
COMPLETED
The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to investigate the value of Orencia in rapidly progressing Rheumatoid Arthritis (RA).
Eligibility Criteria
Inclusion
- 18 years of age at enrollment
- Confirmed diagnosed with RA
- Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab with a record of the start date at the practice site
Exclusion
- Does not have at least 1 or more poor RA prognostic factor: Evidence of joint erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP levels, Increased ESR levels
- Was followed at the site for less than 1 year since biologic treatment initiation
- Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, anal fistula
- Other protocol defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
March 16 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 17 2019
Estimated Enrollment :
265 Patients enrolled
Trial Details
Trial ID
NCT03331393
Start Date
March 16 2017
End Date
January 17 2019
Last Update
July 6 2022
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Beverly Hills, California, United States, 90212
2
Local Institution - 0005
Gainesville, Georgia, United States, 30501
3
Local Institution
Coeur d'Alene, Idaho, United States, 83814-2644
4
Local Institution - 0007
Eagan, Minnesota, United States, 55121